Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A multifocal, unisystem form of Langerhans-cell histiocytosis. There is involvement of multiple sites in one organ system, most frequently the bone. Patients are usually young children presenting with multiple destructive bone lesions.
14 clinical trials registered, 9 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE3, 8 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05915208](https://clinicaltrials.gov/study/NCT05915208) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:07 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Histiocytic Disorder Follow-up Study |
— |
University of Alabama at Birmingham |
RECRUITING |
[NCT04665674](https://clinicaltrials.gov/study/NCT04665674) | Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study | — | Assistance Publique - Hôpitaux de Paris | RECRUITING |
[NCT04943224](https://clinicaltrials.gov/study/NCT04943224) | Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients | PHASE2 | Anna Raciborska | RECRUITING |
[NCT04943211](https://clinicaltrials.gov/study/NCT04943211) | Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging | PHASE3 | Anna Raciborska | RECRUITING |
[NCT04943198](https://clinicaltrials.gov/study/NCT04943198) | Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis | PHASE2 | Anna Raciborska | RECRUITING |
11 publications have been identified in PubMed for hand-Schuller-Christian disease. Research spans Case Report / Case Series (73%), Review / Meta-Analysis (18%), and Epidemiology / Natural History (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 73% |
Research summaries | 2 | 18% |
Disease patterns and progression | 1 | 9% |
Diomeda F (2026). [PMID: 41597120](https://pubmed.ncbi.nlm.nih.gov/41597120/). *Children (Basel)*. [Review / Meta-Analysis]
Xiao D (2026). [PMID: 41979620](https://pubmed.ncbi.nlm.nih.gov/41979620/). *Clin Lab*. [Case Report / Case Series]
Latifi A (2026). [PMID: 42161431](https://pubmed.ncbi.nlm.nih.gov/42161431/). *Cancer Rep (Hoboken)*. [Case Report / Case Series]
Sláma T (2025). [PMID: 38353855](https://pubmed.ncbi.nlm.nih.gov/38353855/). *J Cancer Surviv*. [Epidemiology / Natural History]
Stoppino LP (2025). [PMID: 40727890](https://pubmed.ncbi.nlm.nih.gov/40727890/). *Radiol Case Rep*. [Case Report / Case Series]
Saliba T (2025). [PMID: 41280885](https://pubmed.ncbi.nlm.nih.gov/41280885/). *Acta Radiol Open*. [Case Report / Case Series]
Senthilkumar P (2025). [PMID: 41357441](https://pubmed.ncbi.nlm.nih.gov/41357441/). *J Indian Soc Periodontol*. [Case Report / Case Series]
Hua D (2025). [PMID: 41398830](https://pubmed.ncbi.nlm.nih.gov/41398830/). *Medicine (Baltimore)*. [Case Report / Case Series]
Li J (2025). [PMID: 40259405](https://pubmed.ncbi.nlm.nih.gov/40259405/). *Orphanet J Rare Dis*. [Case Report / Case Series]
Liu L (2024). [PMID: 39058803](https://pubmed.ncbi.nlm.nih.gov/39058803/). *Medicine (Baltimore)*. [Review / Meta-Analysis]